Quantres Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Quantres Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2,600	Closed	-$431K	–	232
2018 Q4	$431K	Buy	+2,600	New	+$451K	0.27%	124
2018 Q3	–	Sell	-4,500	Closed	-$765K	–	288
2018 Q2	$765K	Buy	4,500 +1,200	+36%	+$186K	0.44%	78
2018 Q1	$538K	Buy	3,300 +1,200	+57%	+$196K	0.33%	85
2017 Q4	$315K	Sell	2,100 -14,700	-88%	-$2.18M	0.2%	163
2017 Q3	$2.55M	Buy	16,800 +8,800	+110%	+$1.32M	1.64%	10
2017 Q2	$1.03M	Sell	8,000 -10,500	-57%	-$1.26M	0.67%	51
2017 Q1	$2.02M	Buy	18,500 +7,600	+70%	+$669K	1.3%	18
2016 Q4	$803K	Sell	10,900 -4,700	-30%	-$382K	0.56%	66
2016 Q3	$1.36M	Buy	15,600 +12,500	+403%	+$1.18M	0.84%	35
2016 Q2	$267K	Buy	+3,100	New	+$268K	0.17%	145
2015 Q2	–	Sell	-18,900	Closed	-$2.23M	–	217
2015 Q1	$2.23M	Buy	+18,900	New	+$2.26M	2.23%	6
2014 Q2	–	Sell	-4,800	Closed	-$339K	–	232
2014 Q1	$339K	Buy	+4,800	New	+$380K	0.4%	105

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Quantres Asset Management's VRTX Position: Q1 2019 in Review

Quantres Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2019, closing a stake of 2,600 shares — an estimated $431K sold.

Quantres Asset Management first reported a position in VRTX in Q1 2014 and held it in 12 quarters. The position peaked at $2.55M in Q3 2017. 737 funds tracked by Wall St. Rank hold VRTX as of Q1 2019.

Quantres Asset Management reported no remaining Vertex Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Quantres Asset Management sold 2,600 Vertex Pharmaceuticals shares in Q1 2019, an estimated $431K.
Quantres Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2014 and held it in 12 quarters.
Quantres Asset Management's Vertex Pharmaceuticals position peaked at $2.55M in Q3 2017.
737 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2019.

Based on Quantres Asset Management's 13F filing for Q1 2019, filed 12 Apr 2019.